MapleStory Fest at Home 2020 Unites Maplers Around the World with All-Digital Event
16.11.2020 17:00:00 EET | Business Wire | Press release
Maplers around the world gathered to celebrate their favorite games: MapleStory and MapleStory M . Garnering over 20,000 views, MapleStory Fest 2020 at Home brought fans together for the virtual festivities. Fans enjoyed special announcements, greetings from developers, live engagement events, including quizzes, a fan art contest, and several giveaways.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005446/en/
MapleStory Fest at Home 2020 Banner (Graphic: Business Wire)
The event kicked off with a teaser of MapleStory M’s highly anticipated new Demon Avenger class available in-game starting on December 1. MapleStory M developers also answered community questions based on feedback gathered through various platforms announcing several improvements.
Maplers were also treated to the latest news surrounding MapleStory with the announcement of the Awake two-part content update. The first installment, Awake: Ascend to Mastery, will be landing on November 18 featuring new 5th Job skills for all classes, Grand Athenaeum Episode 6: Sharenian Knights and character level-up events, including the return of Burning World.
The second part of the update, Awake: Flicker of Light, will include Reboot world improvements with the addition of Zero character creation, new areas, seasonal events, and exclusive Global MapleStory content slated to hit on December 16.
After receiving hundreds of submissions, viewers came together to vote for the most creative fan art and MapleStory and MapleStory M guild group screenshots. During the event, a special community video was shown featuring MapleStory and MapleStory M players sharing their favorite Maple world memories.
Winners of the MapleStory Fest 2020 in-game prizes were also announced throughout the event from over 6,000 entries received. Nexon also partnered with HyperX to create an exclusive MapleStory Fest 2020 Cloud Alpha headset raffled during a social media promotion. Hyper X also provided various free products raffled throughout the event.
On November 12, Nexon Korea's CEO, Jung-Hun Lee, announced a collaboration event between popular anime series, Attack on Titan , and its mobile MMORPG, MapleStory M . A key figure from Attack on Titan will offer special quests until November 25. Based on the manga "Shingeki no Kyojin" by Hajime Isayama originally serialized in the Monthly BESSATSU SHONEN magazine published by Kodansha Ltd. ©Hajime Isayama,Kodansha/"ATTACK ON TITAN"Production Committee. All Rights Reserved.
To learn more about the content updates announced at the event, please visit the MapleStory Fest 2020 at Home website and follow @MapleStory and @PlayMapleM on Twitter for the latest news.
Assets:
- MapleStory Fest 2020 Assets
- MapleStory Fest 2020 at Home Highlights Video
- MapleStory Awake Update Preview
- MapleStory M Demon Avenger Trailer
- MapleStory M Attack on Titan Assets
Social Media:
- MapleStory: Twitch / Facebook / Twitter / YouTube / Website
- MapleStory M: Twitch / Facebook / Twitter / YouTube / Website
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 15 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About MapleStory M https://maplestorym.nexon.com/
MapleStory M, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the epic franchise. MapleStory M quickly reached 10 million downloads within 100 days after global launch and recently celebrated its 2-year anniversary with 16 million global downloads.
About Nexon America Inc. https://www.nexon.com
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005446/en/
Contact information
Nexon America
Cynthia Lezama
clezama@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom